SCHEMBL4764980

SCHEMBL4764980

CCCN(Cc1ccc(F)cc1F)C(=O)CCc1ccc(OCc2ccccc2C(=O)OC)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 5/20 0.43
FFAR1 O14842 4/20 0.42
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAOB P27338 1/20 0.41
HTR2A P28223 4/20 0.41
KCNK3 O14649 1/20 0.41
KCNK5 O95279 1/20 0.41
KCNA5 P22460 1/20 0.41
KCNK17 Q96T54 1/20 0.41
KCNK9 Q9NPC2 1/20 0.41
PPARA Q07869 1/20 0.40
LTB4R2 Q9NPC1 1/20 0.39
GSK3B P49841 1/20 0.39
BACE1 P56817 1/20 0.39
PTPN1 P18031 1/20 0.39
MME P08473 1/20 0.38
ACE P12821 1/20 0.38
CPA1 P15085 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4631046 0.94 PPARG (0.42) FFAR4FFAR1POLBMAPTSMN1; SMN2
SCHEMBL4630741 0.91 LTB4R2 (0.46) FFAR4FFAR1MAOBHTR2APPARA
Tert-Butylamine SCHEMBL5311320 0.88 LTB4R2 (0.43) FFAR4FFAR1MAOBHTR2APPARA
SCHEMBL4630557 0.86 HTR2A (0.47) MAOBHTR2AKCNK3KCNK5KCNA5
SCHEMBL4630408 0.86 LTB4R2 (0.48) FFAR4FFAR1HTR2APPARALTB4R2
SCHEMBL4630463 0.85 LPAR1 (0.45) FFAR4FFAR1POLBMAPTSMN1; SMN2
Tert-Butylamine SCHEMBL5329291 0.83 LTB4R2 (0.45) FFAR4FFAR1HTR2APPARALTB4R2
Amantadine SCHEMBL5312024 0.82 HTR2A (0.39) FFAR4FFAR1HTR2APPARALTB4R2
SCHEMBL4964423 0.82 HTR2A (0.42) FFAR4MAPTHTR2AKCNK3KCNK5
SCHEMBL4629875 0.81 PPARG (0.41) PPARALTB4R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1517883-B8 ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE ASTRAZENECA AB (SE) 2008-05-21 EP disclosed
US-7355069-B2 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance ASTRAZENECA AB (SE) 2008-04-08 US disclosed
EP-1517883-B1 ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE ASTRAZENECA AB (SE) 2008-02-13 EP disclosed
US-20050256198-A1 Ortho-substituted benzoic acid derivatives for the treatmetn of insulin resistance ASTRAZENECA AB (SE) 2005-11-17 US disclosed
EP-1517883-A1 ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE AstraZeneca AB (SE) 2005-03-30 EP disclosed
WO-2004000790-A1 ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE ASTRAZENECA AB (SE) 2003-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256198-A1 Ortho-substituted benzoic acid derivatives for the treatmetn of insulin resistance GPR119, INSR, IRS1 FFAR4 565/4885FFAR1 157/4885POLB 2492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.